Skip to main content

Table 3 Number (%) of patients who had at least one measure of LDLC <70 mg/dl, and number (%) of LDLC measurements of LDLC with LDLC <70 mg/dl through follow-up on ALI 75 mg every 2 weeks (n = 29), or Alirocumab 150 mg (n = 18) or Evolocumab 140 mg (n = 22) every 2 weeks (ALI-EVO)

From: Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study

 

HeFH only, 25 patients

CVD only, 25 patients

HeFH & CVD, 19 patients

Total cohort, 69 patients

Entry LDLC 25th, 50th, 75th percentile [141, 156, 181 mg/dl]

Entry LDLC 25th, 50th, 75th percentile [90, 110, 149 mg/dl]

Entry LDLC 25th, 50th, 75th percentile [106, 156, 204 mg/dl]

Entry LDLC 25th, 50th, 75th percentile [110, 143, 172 mg/dl]

 

number (%) of patients had LDLC < 70 mg/dl at least once during follow up,

number (%) of measures with LDLC <70 mg/dl during follow up

ALI 75 mg/2 weeks

Total 29 patients

65 LDLC measurements

2/6 (33%) patients

8/17 (47%) LDLC measurements

11/17 (65%) patients

22/35 (63%) LDLC measurements

2/6 (33%) patients

8/13 (62%) LDLC measurements

15/29 (52%) patients

38/65 (58%) LDLC measurements

ALI-EVO

Total 40 patients

59 LDLC measurements

9/19 (47%) patients

12/27 (44%) LDLC measurements

6/8 (75%) patients

9/12 (75%) LDLC measurements

5/13 (38%) patients

7/20 (35%) LDLC measurements

20/40 (50%) patients

28/59 (47%) LDLC measurements

All treatment groups

Total 69 patients

124 LDLC measurements

11/25 (44%) patients

20/44 (45%) LDLC measurements

17/25 (68%) patients

31/47 (66%) LDLC measurements

7/19 (37%) patients

15/33 (45%) LDLC measurements

35/69 (51%) patients

66/124 (53%) LDLC measurements